Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02576548 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
NCT02576548 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 47 participants.
The verdict
NCT02576548, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
Study Summary
This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.
Interventions
- BIOLOGICAL MEDI4276
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2015-09-23 |
| Est. Completion | 2018-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02576548
The ClinicalTrials.gov registry entry for NCT02576548 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI4276 is the first listed.
NCT02576548 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02576548 about?
NCT02576548 is a clinical study titled "A Phase 1/2 Study of MEDI4276 in Adults Subjects With Select HER2-expressing Advanced Solid Tumors.". This research study is designed to evaluate an experimental drug, MEDI4276, in treating breast and stomach (gastric) cancer.
What is the current status of trial NCT02576548?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2015-09-23. Estimated completion is 2018-05-23.
What interventions are being tested in trial NCT02576548?
The interventions under investigation include: MEDI4276 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02576548?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.